Penile Traction Does Not Interfere with IFN Therapy for PD
Study reveals no significant impact on changes in penile curvature or length.
ORLANDO—Routine use of penile traction therapy during interferon (IFN) therapy for Peyronie's disease (PD) does not affect therapeutic outcome as it pertains to penile curvature and length, according to study findings presented at the American Urological Association's 2014 annual meeting.
The retrospective study, by Landon Trost, MD, of Mayo Clinic in Rochester, Minn., and colleagues, included 124 men (mean age 54 years, range 25-76) who underwent a median of 12 IFN injections. The cohort had a mean pre-treatment curvature of 42.4 degrees. Of these patients, 42 (34%) reported regular use of penile traction therapy (PTT) during the study period. The PTT group and no-PTT groups had a change in curvature of 7.6 and 9.6 degrees, respectively, and an increase in penile length of 0.04 cm and 0.13 cm, respectively, differences that were not statistically significant.
In addition, PTT use did not correlate with patient age, body mass index, years with PD, pre-treatment erectile function, pre-treatment curvature, changes in peak systolic velocity, or resistant index.